PCYOX1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population designed for loss-of-function studies of the PCYOX1 gene in human Raji B lymphocytes. The polyclonal pool harbors heterogeneous CRISPR/Cas9-induced disruptions in the PCYOX1 locus, enabling population-level ablation of gene expression without clonal selection.
Raji cells are an EBV-positive Burkitt lymphoma-derived B lymphocyte line extensively used to model B cell biology, signal transduction, and lymphomagenesis. Their suspension growth and retention of key B cell features make them a robust platform for examining lymphocyte-specific metabolic pathways and oncogenic mechanisms.
PCYOX1 encodes a peroxisomal prenylcysteine oxidase that employs FAD as a cofactor to oxidize prenylcysteine into prenal and cysteine, the terminal step in prenylated protein degradation. Transcriptionally regulated by PPAR??, PCYOX1 acts downstream of lysosomal proteolysis, which liberates prenylcysteine from catabolized prenylated proteins. Its activity is essential for cysteine salvage and prenyl group clearance; disrupting PCYOX1 is predicted to cause prenylcysteine accumulation and imbalances in prenal and cysteine levels, thereby perturbing prenylated protein turnover.
In the Burkitt lymphoma context, this PCYOX1 knockout model enables dissection of how prenylated protein catabolism influences lymphocyte proliferation, survival, and stress responses. Given the abundance of prenylated small GTPases in B cell signaling, defective prenylcysteine metabolism may alter growth and apoptotic setpoints, uncovering context-specific vulnerabilities. The model also facilitates examination of peroxisomal function and cysteine recycling in lymphoma cells, with potential relevance to tissue-specific manifestations of PCYOX1 deficiency.
Applications include mechanistic studies of prenylated protein degradation in B lymphocytes, functional genomics of PCYOX1 in lymphoma, and drug screening for prenylcysteine metabolism modulators. Researchers can employ western blotting, HPLC-based prenylcysteine quantification, RT?qPCR, RNA-seq, metabolomics, proliferation assays, and flow cytometric apoptosis detection to characterize the knockout phenotype. For further details or to inquire about this product, please contact Ascent Research.
